AN OPEN LABEL, PROSPECTIVE, POST MARKETING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF RITUXIMAB WITH GLUCOCORTICOIDS IN ADULT PATIENTS WITH WEGENER'S GRANULOMATOSIS (GRANULOMATOSIS WITH POLYANGIITIS - GPA) OR MICROSCOPIC POLYANGIITIS
Phase of Trial: Phase IV
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Methylprednisolone; Prednisolone; Prednisone
- Indications Granulomatosis with polyangiitis; Microscopic polyangiitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 07 Oct 2019 Planned End Date changed from 30 Jun 2021 to 19 Aug 2020.
- 07 Oct 2019 Planned primary completion date changed from 30 Jun 2021 to 19 Aug 2020.
- 29 Mar 2019 Status changed from suspended to recruiting.